A panel of medical experts discuss treating acute myeloid leukemia (AML), from diagnosis to the different therapies available that give patients the best chance at survival.
EP. 1: What Does an AML Diagnosis Mean?
James McCloskey, MD, and Danielle Marcotulli, APN, RN, MSN, FNP-BC, AOCNP give a brief synopsis of AML, including its definition, the different types of the condition, and a typical patient’s journey.
EP. 2: AML Treatment Selection: Goals, Tests, and Considerations
Cole McCoy, PharmD, and James McCloskey, MD, explain common treatment goals, cytogenetic tests, and considerations that factor into choosing individualized treatment for patients with AML.
EP. 3: Recent Treatment Updates for Managing Patients With AML
Cole McCoy, PharmD, shares recent changes in the AML treatment landscape, including updates to the NCCN guidelines.
EP. 4: Determining Intensive Chemotherapy Eligibility in AML
Two medical professionals reveal what factors into intensive chemotherapy consideration and common toxicities found when undergoing treatment.
EP. 5: First-Line Treatment Options and Genetic Mutations
Cole McCoy, PharmD, and Dr James McCloskey explain first-line treatment options for different types of AML, how genetic mutation affect treatment decisions, and the treatment option for patients with AML that are unfit for intensive chemotherapy.
EP. 6: Assessing Clinical Trials and First-Line AML Treatment Options
Medical experts elaborate on the AG221-AML-005 and AGILE studies and their results, as well as how we assess first-line treatment response.
EP. 7: A Care Team’s Individual Roles When Treating AML
The panel describes the various roles and responsibilities for each member of an AML management care team.
EP. 8: Evaluating Patients and Novel Agents for AML Maintenance Therapy
Dr James McCloskey discusses patient selection for AML maintenance therapy, as well as novel agents that are being evaluated in this setting.
EP. 9: Additional Agents for AML Maintenance Therapy
Cole McCoy, PharmD, and Danielle Marcotulli, APN, RN, MSN, FNP-BC, AOCNP explain the additional agents being studied as maintenance therapy options.
EP. 10: Data Supporting the Use of Maintenance Therapy in AML
James McCloskey, MD, analyzes result data from the QUAZAR AML-001 trial that focused on oral azacitidine.
EP. 11: Oral AML Maintenance Therapy Options
Cole McCoy, PharmD, details his experiences with oral maintenance therapies, specifically oral azacitidine.
EP. 12: How Maintenance Therapy Has Impacted AML Treatment
Cole McCoy, PharmD, considers if maintenance therapy is standard of care and what is involved with appropriate transitions upon discharge.
EP. 13: Treating Relapsed/Refractory AML
Drs McCoy and McCloskey discuss relapsed/refractory AML, including treatment goals and options.
EP. 14: The Future of Treating AML
The panel concludes with their thoughts on the future of the AML treatment landscape.
2 Clarke Drive Cranbury, NJ 08512